Miniaturized three-dimensional cancer model for drug evaluation

Assay and Drug Development Technologies

Volumn 11, Issue 7, 2013, Pages 435-448

  Lovitt, Carrie J ^a   Shelper, Todd B ^a   Avery, Vicky M ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETORPHAN; AMMONIA; CERIVASTATIN; CICLOPIROXOLAMINE; DIGITOXIN; MADURAMICIN; MITOXANTRONE; MYCOPHENOLIC ACID; RUBITECAN; SALINOMYCIN; SIMVASTATIN; TOPOTECAN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER MODEL; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL CULTURE; HYDROGEL; IC 50; IMAGE ANALYSIS; LABORATORY DEVICE; MONOLAYER CULTURE; REPRODUCIBILITY; THREE DIMENSIONAL CELL CULTURE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; APOPTOSIS; BATCH CELL CULTURE; BIOASSAY; BIOLOGICAL MODEL; BREAST NEOPLASMS; CELL SURVIVAL; DEVICE FAILURE ANALYSIS; DEVICES; DRUG EFFECTS; ELECTRONICS; EQUIPMENT DESIGN; FEMALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BATCH CELL CULTURE TECHNIQUES; BIOLOGICAL ASSAY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FEMALE; HUMANS; MINIATURIZATION; MODELS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84884545724     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2012.483     Document Type: Article

References (59)

1. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9: 539-549.
2. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-252.
3. Lai Y, Asthana A, Kisaalita WS: Biomarkers for simplifying HTS 3D cell culture platforms for drug discovery: the case for cytokines. Drug Discov Today 2011;16:293-297.
4. Astashkina A, Mann B, Grainger DW: A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther 2012;134:82-106.
5. Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-592. (Pubitemid 44140857)
6. Friedrich J, Ebner R, Kunz-Schughart LA: Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge? Int J Radiat Biol 2007;83: 849-871. (Pubitemid 350219104)
7. Moulder JE, Rockwell S: Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-341.
8. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988;240:177-184.
9. Mueller-Klieser W: Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol 1997;273(4 Pt 1):C1109-C1123 (Pubitemid 127797683)
10. Bryce NS, Zhang JZ, Whan RM, Yamamoto N, Hambley TW: Accumulation of an anthraquinone and its platinum complexes in cancer cell spheroids: the effect of charge on drug distribution in solid tumour models. Chem Commun 2009;19:2673-2675.
11. Asthana A, Kisaalita WS: Microtissue size and hypoxia in HTS with 3D cultures. Drug Discov Today 2012;17:810-817.
12. Kisaalita WS: 3D Cell-Based Biosensors in Drug Discovery Programs: Microtissue Engineering for High Throughput Screening. CRC Press, Boca Raton, FL, 2010.
13. Caponigro G, Sellers WR: Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov 2011;10:179-187.
14. Prestwich GD: Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Acc Chem Res 2008;41:139-148.
15. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S: High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011;136:473-478.
16. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA: Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010;148:3-15.
17. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA: Spheroid-based drug screen: considerations and practical approach. Nat Protocols 2009;4:309-324.
18. Justice BA, Badr NA, Felder RA: 3D cell culture opens new dimensions in cellbased assays. Drug Discov Today 2009;14:102-107.
19. Burdett E, Kasper FK, Mikos AG, Ludwig JA: Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng Part B Rev 2010;16:351-359.
20. Griffith LG, Swartz MA: Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006;7:211-224.
21. Haycock JW: 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 2011;695:1-15.
22. Lee J, Cuddihy MJ, Kotov NA: Three-dimensional cell culture matrices: state of the art. Tissue Eng Part B Rev 2008;14:61-86.
23. Yuhas JM, Tarleton AE, Harman JG: In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo. Cancer Res 1978;38:3595-3598. (Pubitemid 9045176)
24. Kleinman HK, Martin GR: Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005;15:378-386. (Pubitemid 41140305)
25. Cukierman E, Pankov R, Yamada KM: Cell interactions with three-dimensional matrices. Curr Opin Cell Biol 2002;14:633-639. (Pubitemid 35247748)
26. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73. (Pubitemid 29278954)
27. Seeger H, Wallwiener D, Mueck AO: Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 2003;111:47-48. (Pubitemid 36336817)
28. Gbelcova H, Lenicek M, Zelenka J, et al.: Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 2008;122:1214-1221. (Pubitemid 351287219)
29. Zhou H, Shen T, Luo Y, et al.: The antitumor activity of the fungicide ciclopirox. Int J Cancer 2010;127:2467-2477.
30. Denoyelle C, Vasse M, Korner M, et al.: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-1148. (Pubitemid 32737327)
31. Gupta PB, Onder TT, Jiang G, et al.: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-659.
32. Zhang GN, Liang Y, Zhou LJ, et al.: Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett 2011;313:137-144.
33. Von Hoff DD, Coltman CA Jr, Forseth B: Activity of mitoxantrone in a human tumor cloning system. Cancer Res 1981;41:1853-1855. (Pubitemid 11114584)
34. Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortes F: Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 2005;68:1642-1645. (Pubitemid 41789573)
35. Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, Diamandis EP: Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther 2011;10:2083-2093.
36. Lin T, Meng L, Tsai RY: GTP depletion synergizes the anti-proliferative activity of chemotherapeutic agents in a cell type-dependent manner. Biochem Biophys Res Commun 2011;414:403-408.
37. Rodriguez-Pascual J, Sha P, Garcia-Garcia E, et al.: A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Invest New Drugs 2013;31:14-19.
38. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, Giovanella BC: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 1993;53:1577-1582. (Pubitemid 23113233)
39. Clark JW: Rubitecan. Expert Opin Investig Drugs 2006;15:71-79. (Pubitemid 43034152)
40. Jonsson E, Fridborg H, Csoka K, et al.: Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 1997;76:211-219. (Pubitemid 27279661)
41. Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A: Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res 1997;88:760-769. (Pubitemid 27404021)
42. Nirmalanandhan VS, Duren A, Hendricks P, Vielhauer G, Sittampalam GS: Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev Technol 2010;27:27.
43. Harma V, Virtanen J, Makela R, et al.: A comprehensive panel of threedimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010;5:e10431.
44. Vinci M, Gowan S, Boxall F, et al.: Advances in establishment and analysis of 3D tumour spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012;10:29.
45. Lee GY, Kenny PA, Lee EH, Bissell MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007;4:359-365. (Pubitemid 46766981)
46. Dufau I, Frongia C, Sicard F, et al.: Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 2012;12:15.
47. Gutierrez-Barrera AM, Menter DG, Abbruzzese JL, Reddy SA: Establishment of three-dimensional cultures of human pancreatic duct epithelial cells. Biochem Biophys Res Commun 2007;358:698-703. (Pubitemid 46802448)
48. Froeling FEM, Mirza TA, Feakins RM, et al.: Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, {beta}-catenin, and ezrin expression in tumor cells. Am J Pathol 2009;175:636-648.
49. Kenny PA, Lee GY, Myers CA, et al.: The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007;1:84-96. (Pubitemid 46776616)
50. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ: HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010;122:35-43.
51. Pickl M, Ries CH: Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009;28:461-468.
52. Pampaloni F, Reynaud EG, Stelzer EH: The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007;8:839-845. (Pubitemid 47462131)
53. Elliott NT, Yuan F: A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 2011;100:59-74.
54. Yamada KM, Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-610. (Pubitemid 47268064)
55. Rodday B, Hirschhaeuser F, Walenta S, Mueller-Klieser W: Semiautomatic growth analysis of multicellular tumor spheroids. J Biomol Screen 2011;16:1119-1124.
56. O'Brien J, Wilson I, Orton T, Pognan F: Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000;267:5421-5426.
57. Sitohy B, Nagy JA, Dvorak HF: Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-1914.
58. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
59. Elenbaas B, Weinberg RA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001;264:169-184. (Pubitemid 32989090)